Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Quince Therapeutics Inc (Quince Therapeutics) is a biotechnology company that develops treatments for rare diseases by utilizing a patient's own biology. The company's lead product is eDSP (EryDex) for the treatment of ataxia-telangiectasia (A-T) using its proprietary autologous intracellular drug encapsulation (AIDE) technology. Quince Therapeutics' products are primarily used for rare neurodegenerative and immunodeficiency disorders, with applications in the healthcare industry. The company operates in the US, Italy, and the UK. Quince Therapeutics is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
Suite 273, 611 Gateway Blvd, San Francisco, California, 94080
Website
quincetx.com
Telephone
1 415 9105717
No of Employees
38
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
QNCX (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-47.8%
(2024 vs 2023)
Market Cap*
$20.9M
* As of and is in US$
Quince Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| eDSP: |
| Ataxia-Telangiectasia |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In August, the company entered into a partnership with Option Care Health for the development of encapsulated dexamethasone sodium phosphate for Ataxia-Telangiectasia treatment. |
| 2024 | Others | In June, the company secured fast-track designation from the U.S. Food and Drug Administration for its EryDex System to treat patients with Ataxia-Telangiectasia. |
| 2023 | Acquisitions/Mergers/Takeovers | In October, the company announced the completion of its acquisition of EryDel S.p.A., a late-stage biotech company. |
Competitor Comparison
| Key Parameters | Quince Therapeutics Inc | AbbVie Inc | Cenna Biosciences Inc | Acumen Pharmaceuticals Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | San Francisco | North Chicago | La Jolla | Newton |
| State/Province | California | Illinois | California | Massachusetts |
| No. of Employees | 38 | 57,000 | - | 60 |
| Entity Type | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dirk Thye, M.D. | Chief Executive Officer; Chief Medical Officer; Director | Executive Board | 2022 | 55 |
| Brendan Hannah | Chief Business Officer; Chief Compliance Officer; Chief Operating Officer | Senior Management | 2022 | 40 |
| Giovanni Mambrini | Chief Technology Officer | Senior Management | - | - |
| Charles Ryan, Ph.D. | President | Senior Management | 2023 | 60 |
| Maureen Roden | Vice President - Clinical Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer